GAMMA Investing LLC Buys 5,466 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

GAMMA Investing LLC increased its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 4,555.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,586 shares of the company's stock after purchasing an additional 5,466 shares during the quarter. GAMMA Investing LLC's holdings in Mirum Pharmaceuticals were worth $252,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Jones Financial Companies Lllp increased its holdings in shares of Mirum Pharmaceuticals by 100.0% during the fourth quarter. Jones Financial Companies Lllp now owns 714 shares of the company's stock worth $30,000 after buying an additional 357 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in Mirum Pharmaceuticals during the 4th quarter worth $35,000. GF Fund Management CO. LTD. acquired a new position in Mirum Pharmaceuticals in the 4th quarter worth about $42,000. AlphaQuest LLC raised its position in Mirum Pharmaceuticals by 969.6% in the fourth quarter. AlphaQuest LLC now owns 1,829 shares of the company's stock valued at $76,000 after purchasing an additional 1,658 shares during the last quarter. Finally, Summit Investment Advisors Inc. raised its position in Mirum Pharmaceuticals by 8.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 4,155 shares of the company's stock valued at $172,000 after purchasing an additional 312 shares during the last quarter.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on MIRM. Raymond James Financial restated a "strong-buy" rating on shares of Mirum Pharmaceuticals in a report on Tuesday, May 13th. JMP Securities upped their price target on shares of Mirum Pharmaceuticals from $74.00 to $76.00 and gave the company a "market outperform" rating in a research report on Friday, May 9th. HC Wainwright reaffirmed a "buy" rating and set a $73.00 price target on shares of Mirum Pharmaceuticals in a research note on Monday, May 19th. Finally, Robert W. Baird boosted their price objective on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an "outperform" rating in a research note on Thursday, February 27th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Mirum Pharmaceuticals currently has an average rating of "Buy" and a consensus target price of $65.50.

Mirum Pharmaceuticals Trading Down 0.9%

NASDAQ:MIRM opened at $50.34 on Friday. Mirum Pharmaceuticals, Inc. has a 52 week low of $32.00 and a 52 week high of $54.23. The company has a debt-to-equity ratio of 1.32, a quick ratio of 3.04 and a current ratio of 3.22. The firm's fifty day moving average is $44.31 and its 200-day moving average is $45.03. The firm has a market cap of $2.49 billion, a P/E ratio of -31.27 and a beta of 0.95.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.30) EPS for the quarter, beating analysts' consensus estimates of ($0.35) by $0.05. Mirum Pharmaceuticals had a negative net margin of 20.39% and a negative return on equity of 33.63%. The business had revenue of $111.59 million for the quarter, compared to analysts' expectations of $98.47 million. During the same quarter in the prior year, the firm posted ($0.54) earnings per share. The business's quarterly revenue was up 61.2% compared to the same quarter last year. Equities analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.

Want to see what other hedge funds are holding MIRM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.